{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:12:08Z","timestamp":1793211128056,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pathol.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:08:26Z","timestamp":1766074106000},"page":"189-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Heritable metabolic bone disorders: a guide to current genetic testing and clinical management for adult endocrinologists"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-2476","authenticated-orcid":false,"given":"Shejil","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemima","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita M.C.","family":"De Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.12.001_bib1","article-title":"Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease","author":"Chai","year":"2024","journal-title":"BioRxiv Preprint"},{"key":"10.1016\/j.pathol.2025.12.001_bib2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41436-020-01007-7","article-title":"Individuals with common diseases but with a low polygenic risk score could be prioritized for rare variant screening","volume":"23","author":"Lu","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib3","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","article-title":"A nosology of genetic skeletal disorders: 2023 revision","volume":"191","author":"Unger","year":"2023","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pathol.2025.12.001_bib4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.pathol.2025.12.001_bib5","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.4130","article-title":"Burden of illness in adults with hypophosphatasia: data from the global hypophosphatasia patient registry","volume":"35","author":"Seefried","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117572","article-title":"A real-world analysis of the clinical and healthcare burden associated with osteogenesis imperfecta","volume":"200","author":"Abraham","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.12.001_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.628946","article-title":"Massively parallel sequencing for rare genetic disorders: potential and pitfalls","volume":"11","author":"McInerney-Leo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pathol.2025.12.001_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/bonekey.2013.190","article-title":"Whole exome sequencing is an efficient, sensitive and specific method of mutation detection in osteogenesis imperfecta and Marfan syndrome","volume":"2","author":"McInerney-Leo","year":"2013","journal-title":"Bonekey Rep"},{"key":"10.1016\/j.pathol.2025.12.001_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-021-02927-3","article-title":"A contemporary clinical approach to genetic testing for heritable hyperparathyroidism syndromes","volume":"75","author":"De Sousa","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.pathol.2025.12.001_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/cen.14596","article-title":"A practical guide to genetic testing in endocrinology","volume":"97","author":"Izatt","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.pathol.2025.12.001_bib11","first-page":"17","article-title":"Genetic testing in endocrinology","volume":"39","author":"De Sousa","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.pathol.2025.12.001_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","article-title":"Next-generation sequencing technologies: an overview","volume":"82","author":"Hu","year":"2021","journal-title":"Hum Immunol"},{"key":"10.1016\/j.pathol.2025.12.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117568","article-title":"Next-generation sequencing transforming clinical practice and precision medicine","volume":"551","author":"Yadav","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.pathol.2025.12.001_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/cge.12550","article-title":"Whole exome sequencing is an efficient, sensitive and specific method for determining the genetic cause of short-rib thoracic dystrophies","volume":"88","author":"McInerney-Leo","year":"2015","journal-title":"Clin Genet"},{"key":"10.1016\/j.pathol.2025.12.001_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11914-024-00870-6","article-title":"Genetic evaluation for monogenic disorders of low bone mass and increased bone fragility: what clinicians need to know","volume":"22","author":"Busse","year":"2024","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pathol.2025.12.001_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39571","article-title":"Rates and classification of variants of uncertain significance in hereditary disease genetic testing","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pathol.2025.12.001_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100947","article-title":"The landscape of reported VUS in multi-gene panel and genomic testing: time for a change","volume":"25","author":"Rehm","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib19","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1159\/000495956","article-title":"Loss of tumor suppressor gene function in human cancer: an overview","volume":"51","author":"Wang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.pathol.2025.12.001_bib20","doi-asserted-by":"crossref","first-page":"5S51","DOI":"10.1016\/S0929-693X(18)30014-9","article-title":"Genetics of hypophosphatasia","volume":"24","author":"Mornet","year":"2017","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.pathol.2025.12.001_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2023.11.005","article-title":"Will variants of uncertain significance still exist in 2030?","volume":"4","author":"Fowler","year":"2024","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pathol.2025.12.001_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2016.11.013","article-title":"FGF23-\u03b1Klotho as a paradigm for a kidney-bone network","volume":"100","author":"Kuro-O","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.12.001_bib23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1210\/er.2017-00220","article-title":"X-Linked hypophosphatemia and FGF-23-related hypophosphatemic diseases: Prospect for new treatment","volume":"39","author":"Kinoshita","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pathol.2025.12.001_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pathol.2025.12.001_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116791","article-title":"Prevalence and characteristics of paediatric X-linked hypophosphataemia in Australia and New Zealand: results from the Australian and the New Zealand Paediatric Surveillance Units Survey","volume":"173","author":"Sandy","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.12.001_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphataemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets","volume":"11","author":"Francis","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2025.12.001_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Neilsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pathol.2025.12.001_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.24296","article-title":"Novel PHEX gene locus-specific database: comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH)","volume":"43","author":"Sarafrazi","year":"2021","journal-title":"Hum Mutat"},{"key":"10.1016\/j.pathol.2025.12.001_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pathol.2025.12.001_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-020-05649-w","article-title":"Iron deficiency plays essential roles in the trigger, treatment, and prognosis of autosomal dominant hypophosphatemic rickets","volume":"32","author":"Liu","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/jbmr.3878","article-title":"Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets","volume":"35","author":"Imel","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1005189","article-title":"Osteocytes and the pathogenesis of hypophosphatemic rickets","volume":"13","author":"Yamazaki","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101843","article-title":"Inherited non-FGF23-mediated phosphaturic disorders: a kidney-centric review","volume":"38","author":"Walker","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"21","author":"Haffner","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pathol.2025.12.001_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688309","article-title":"X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10744","article-title":"Asia-Pacific consensus recommendations on X-linked hypophosphatemia: diagnosis, multidisciplinary management, and transition from pediatric to adult care","volume":"7","author":"Munns","year":"2023","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.12.001_bib39","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","article-title":"X-linked hypophosphatemia management in adults: an international working group clinical practice guideline","volume":"110","author":"Khan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with x-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib41","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3390\/genes13122415","article-title":"Impact of X-linked hypophosphatemia on muscle symptoms","volume":"13","author":"Romagnoli","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pathol.2025.12.001_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib43","doi-asserted-by":"crossref","first-page":"ziae118","DOI":"10.1093\/jbmrpl\/ziae118","article-title":"Impact of X-linked hypophosphatemic rickets\/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study","volume":"8","author":"Namba","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.12.001_bib44","first-page":"ziae132","article-title":"Burosumab in adults with X-linked hypophosphatemia: real-world experience from a retrospective study in Sydney","author":"Kumar","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.12.001_bib45","doi-asserted-by":"crossref","first-page":"bvae185","DOI":"10.1210\/jendso\/bvae185","article-title":"Real-world clinical and healthcare resource burden among burosumab-na\u00efve patients with familial hypophosphatemia","volume":"8","author":"Imel","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.pathol.2025.12.001_bib46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib47","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib48","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2025.12.001_bib49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.pathol.2025.12.001_bib50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"Briot","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.pathol.2025.12.001_bib52","doi-asserted-by":"crossref","first-page":"ziae079","DOI":"10.1093\/jbmrpl\/ziae079","article-title":"Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study","volume":"8","author":"Michigami","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.12.001_bib53","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00223-025-01433-2","article-title":"Real-world effectiveness of burosumab in adults with X-linked hypophosphataemia (XLH) in the UK","volume":"116","author":"Bubbear","year":"2025","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib54","article-title":"Confirmatory psychometric validation of the Western Ontario McMaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphataemia (XLH)","author":"Skrinar","year":"2019","journal-title":"Program of ISPOR Europe"},{"key":"10.1016\/j.pathol.2025.12.001_bib55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10689-024-00373-4","article-title":"Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs","volume":"23","author":"Levine","year":"2024","journal-title":"Fam Cancer"},{"key":"10.1016\/j.pathol.2025.12.001_bib57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00223-025-01388-4","article-title":"A mosaic PHEX variant in hypophosphatemic rickets: distinguishing postzygotic mutation from sex chromosome aneuploidy","volume":"116","author":"Lim","year":"2025","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-016-0309-0","article-title":"Hypophosphatasia","volume":"14","author":"Linglart","year":"2016","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pathol.2025.12.001_bib59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","article-title":"Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients","volume":"75","author":"Whyte","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.12.001_bib60","doi-asserted-by":"crossref","first-page":"zjaf141","DOI":"10.1093\/jbmr\/zjaf141","article-title":"Hypophosphatasathia - Pophysiological understanding, preclinical data looking beyond the skeleton, and upcoming treatments","volume":"7","author":"Mill\u00e1n","year":"2025","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib61","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/rheumatology\/41.7.725","article-title":"Genetic studies of disorders of calcium crystal deposition","volume":"41","author":"Timms","year":"2002","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.pathol.2025.12.001_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.a.63781","article-title":"New insights into the landscape of ALPL gene variants in patients with hypophosphatasia from the Global HPP Registry","volume":"194","author":"Kishnani","year":"2024","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pathol.2025.12.001_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1469-1809.2011.00642.x","article-title":"A molecular-based estimation of the prevalence of hypophosphatasia in the European population","volume":"75","author":"Mornet","year":"2011","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.pathol.2025.12.001_bib64","doi-asserted-by":"crossref","first-page":"zjaf124","DOI":"10.1093\/jbmr\/zjaf124","article-title":"Biochemical phenotype of hypophosphatasia in asymptomatic individuals carrying ALPL variants","author":"Montero-Lopez","year":"2025","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib65","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41431-020-00732-6","article-title":"Hypophosphatasia: a genetic-based nosology and new insights in genotype-phenotype correlation","volume":"29","author":"Mornet","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.pathol.2025.12.001_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.2056","article-title":"Not just a carrier: clinical presentation and management of patients with heterozygous disease-causing alkaline phosphatase (ALPL) variants identified through expanded carrier screening","volume":"11","author":"Beck","year":"2023","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000531865","article-title":"Clinical profiles of children with hypophosphatasia prior to treatment with enzyme replacement therapy: an observational analysis from the global HPP registry","volume":"97","author":"Martos-Moreno","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.pathol.2025.12.001_bib68","doi-asserted-by":"crossref","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","article-title":"Hypophosphatasia: clinical manifestation and burden of disease in adult patients","volume":"14","author":"Conti","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bone.2013.01.024","article-title":"Clinical spectrum of hypophosphatasia diagnosed in adults","volume":"54","author":"Berkseth","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.12.001_bib70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jbmr.3928","article-title":"Loss-of-function mutations in the ALPL gene presenting with adult onset osteoporosis and low serum concentrations of total alkaline phosphatase","volume":"35","author":"Alonso","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00223-022-01039-y","article-title":"Diagnostic approach to patients with low serum alkaline phosphatase","volume":"112","author":"Riancho","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib72","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","article-title":"Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys","volume":"65","author":"Weber","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.pathol.2025.12.001_bib73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jmg-2024-110383","article-title":"Disease burden by ALPL variant number in patients with non-life-threatening hypophosphatasia in the Global HPP Registry","volume":"62","author":"Kishnani","year":"2025","journal-title":"J Med Genet"},{"key":"10.1016\/j.pathol.2025.12.001_bib74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","article-title":"Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry","volume":"20","author":"H\u00f6gler","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.pathol.2025.12.001_bib75","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00774-023-01440-z","article-title":"Musculoskeletal pain and muscular weakness as the main symptoms of adult hypophosphatasia in a Spanish cohort: clinical characterization and identification of a new ALPL gene variant","volume":"41","author":"Calmarza","year":"2023","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12020-024-04054-1","article-title":"Diagnosis, treatment, and follow-up of patients with hypophosphatasia","volume":"87","author":"C\u00e1rdenas-Aguilera","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.pathol.2025.12.001_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11914-025-00929-y","article-title":"Pathophysiology of femoral fractures in hypophosphatasia","volume":"23","author":"Tabegna","year":"2025","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pathol.2025.12.001_bib78","first-page":"21","article-title":"Bilateral atypical femoral fractures during denosumab therapy in a patient with adult-onset hypophosphatasia","author":"Warren","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.pathol.2025.12.001_bib79","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1210\/jc.2010-1168","article-title":"Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia","volume":"95","author":"Schalin-J\u00e4ntti","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib80","doi-asserted-by":"crossref","first-page":"bvac159","DOI":"10.1210\/jendso\/bvac159","article-title":"Romosozumab-aqqg in the treatment of osteoporosis in a patient with hypophosphatasia","volume":"6","author":"Khanjee","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.pathol.2025.12.001_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11914-025-00906-5","article-title":"Medical management of hypophosphatasia: review of data on asfotase alfa","volume":"23","author":"Dahir","year":"2025","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.pathol.2025.12.001_bib82","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","article-title":"Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults","volume":"35","author":"Khan","year":"2024","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib83","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.pathol.2025.12.001_bib85","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/hum.2024.191","article-title":"Comprehensive review of osteogenesis imperfecta: current treatments and future innovations","volume":"36","author":"Chaugule","year":"2025","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.pathol.2025.12.001_bib86","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.pathol.2025.12.001_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pathol.2025.12.001_bib88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis imperfecta: mechanisms and signalling pathways connecting classical and rare OI types","volume":"43","author":"Jovanovic","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.pathol.2025.12.001_bib89","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00223-024-01248-7","article-title":"A dyadic nosology for osteogenesis imperfecta and bone fragility syndromes 2024","volume":"115","author":"Sillence","year":"2024","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jbmr.2920","article-title":"Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study","volume":"32","author":"Folkestad","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib91","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/crj.12092","article-title":"Spinal deformities and lung function in adults with osteogenesis imperfecta","volume":"8","author":"Wekre","year":"2014","journal-title":"Clin Respir J"},{"key":"10.1016\/j.pathol.2025.12.001_bib92","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: an update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pathol.2025.12.001_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis imperfecta: new perspectives from clinical and translational research","volume":"3","author":"Tauer","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.pathol.2025.12.001_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pathol.2025.12.001_bib95","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00223-024-01293-2","article-title":"Dental abnormalities in osteogenesis imperfecta: a systematic review","volume":"115","author":"Ventura","year":"2024","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib96","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jbmr\/zjae197","article-title":"Cardiovascular disease in adults with osteogenesis imperfecta: clinical characteristics, care recommendations, and research priorities identified using a modified Delphi technique","volume":"40","author":"Folkestad","year":"2025","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib97","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1080\/07853890.2021.1980819","article-title":"Pathophysiology of respiratory failure in patients with osteogenesis imperfecta: a systematic review","volume":"53","author":"Storoni","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib98","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00198-024-07051-2","article-title":"Demographics and medical burden of osteogenesis imperfecta: a nationwide database analysis","volume":"35","author":"Shih","year":"2024","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib99","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1186\/s12889-024-20555-0","article-title":"The IMPACT Survey: the humanistic impact of osteogenesis imperfecta in adults","volume":"24","author":"van Welzenis","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.pathol.2025.12.001_bib100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-023-02643-3","article-title":"Systematic review of health related-quality of life in adults with osteogenesis imperfecta","volume":"18","author":"McDonald","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pathol.2025.12.001_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13023-023-02728-z","article-title":"Quality of life of pediatric and adult individuals with osteogenesis imperfecta: a meta-analysis","volume":"18","author":"Wehrli","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pathol.2025.12.001_bib102","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1203\/00006450-198303000-00007","article-title":"Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda","volume":"17","author":"Baron","year":"1983","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib103","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib104","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2005-2036","article-title":"Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy","volume":"91","author":"Rauch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib106","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pathol.2025.12.001_bib107","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib108","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib109","first-page":"108","article-title":"Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up","volume":"66","author":"Pav\u00f3n de Paz","year":"2019","journal-title":"Endocrinol Diabetes Nutr (Engl Ed"},{"key":"10.1016\/j.pathol.2025.12.001_bib110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-017-0236-9","article-title":"Long-term effects of neridronate in adults with osteogenesis imperfecta: an observational three-year Italian study","volume":"100","author":"Viapiana","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib111","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","article-title":"Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists","volume":"23","author":"Bradbury","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib113","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm7120479","article-title":"Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series","volume":"7","author":"Kobayashi","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib114","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.pathol.2025.12.001_bib115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.pathol.2025.12.001_bib116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pathol.2025.12.001_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078164","article-title":"Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta","volume":"13","author":"Hald","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.pathol.2025.12.001_bib118","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib119","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","article-title":"Setrusumab for the treatment of osteogenesis imperfecta: 12-month results Q4 from the phase 2b asteroid study","volume":"39","author":"Glorieux","year":"2024","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2025.12.001_bib121","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152571","article-title":"Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta","volume":"132","author":"Song","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pathol.2025.12.001_bib122","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jbmr.4549","article-title":"Curative cell and gene therapy for osteogenesis imperfecta","volume":"37","author":"Schindeler","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pathol.2025.12.001_bib123","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biom11101493","article-title":"Osteogenesis imperfecta: current and prospective therapies","volume":"11","author":"Botor","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.pathol.2025.12.001_bib124","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajmg.c.31459","article-title":"What every clinical geneticist should know about testing for osteogenesis imperfecta in suspected child abuse cases","volume":"169","author":"Pepin","year":"2015","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302525003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:48:45Z","timestamp":1770745725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302525003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0031302525003502"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.12.001","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heritable metabolic bone disorders: a guide to current genetic testing and clinical management for adult endocrinologists","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Royal College of Pathologists of Australasia.","name":"copyright","label":"Copyright"}]}}